Synthroid vs Armour Thyroid: What to Do When One Fails

What Makes Synthroid and Armour Thyroid Different

Synthroid and Armour Thyroid both treat hypothyroidism, but they contain different hormones. Synthroid delivers only synthetic T4 (levothyroxine). Armour Thyroid is porcine-derived desiccated thyroid extract that contains T4, T3, T2, T1, and iodine in a fixed 4:1 T4-to-T3 ratio by weight.

The T4-Only Argument

The body converts T4 to the active hormone T3 through peripheral deiodinase enzymes. In most patients this conversion is adequate, which is why levothyroxine monotherapy works well. The 2014 American Thyroid Association guidelines state that levothyroxine "remains the standard of care for the treatment of hypothyroidism" because of its consistent potency, long half-life of about seven days, and extensive safety record [1].

Why T3 Content Matters for Some Patients

A subset of patients carry variants in the deiodinase type 2 gene (DIO2). These variants may impair conversion of T4 to T3, leaving circulating T3 lower than expected even when TSH is normal [2]. Adding exogenous T3, either as liothyronine or as the T3 naturally present in DTE, could theoretically restore intracellular T3 in these individuals. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that DIO2 polymorphisms are associated with impaired psychological well-being on T4 monotherapy [2].

Pharmacokinetic Difference That Matters Clinically

Armour Thyroid's T3 component has a short half-life of roughly 8 hours, compared to T4's 7-day half-life. This produces a T3 peak about 2 to 4 hours after ingestion [3]. Some patients notice palpitations or anxiety during that peak. Twice-daily dosing of DTE can blunt this effect, and a 2020 systematic review in Frontiers in Endocrinology recommended split dosing specifically for this reason [3].

The Evidence: What Clinical Trials Actually Show

The most cited head-to-head trial is Hoang et al. (2013, J Clin Endocrinol Metab, N=70), a randomized crossover study comparing DTE to levothyroxine over two 16-week treatment periods [4]. Results were specific and worth quoting in full.

Hoang et al. 2013: Key Findings

Patients receiving DTE lost a mean of 4 pounds more than those on levothyroxine (P<0.001) [4]. Forty-nine percent of participants preferred DTE at the end of the trial versus 19% who preferred levothyroxine, with 33% expressing no preference [4]. Cognitive scores and mood did not differ significantly between arms, but the weight and preference data were strong enough that the authors concluded DTE "did not result in adverse outcomes and may be preferred by some patients" [4].

A 2019 retrospective cohort of 769 patients published in the Journal of Clinical Endocrinology and Metabolism found that DTE users had similar cardiovascular event rates to levothyroxine users over a median follow-up of 5 years, addressing one of the historical safety concerns about DTE's T3 content [5].

The Persistent-Symptom Problem on Levothyroxine

The TRUST trial (N=737, NEJM 2017) randomized older hypothyroid adults to levothyroxine titrated to TSH 0.25 to 2.5 mU/L or placebo and found no significant improvement in fatigue or quality of life scores [6]. This does not mean levothyroxine fails everyone. It suggests that in some patients, thyroid symptoms persist for reasons beyond TSH normalization, and that T4-to-T3 conversion efficiency, tissue-level thyroid hormone sensitivity, or comorbid conditions may account for residual complaints.

A survey-based study published in Thyroid (2018, N=12,146) found that patients taking DTE or combination T4/T3 therapy reported significantly higher satisfaction scores than those on levothyroxine alone [7].

Where the Evidence Has Gaps

No large randomized controlled trial has compared DTE to levothyroxine with quality of life as a primary endpoint in a population specifically selected for persistent symptoms. The Hoang trial was 70 patients. The 2019 cohort was retrospective. Clinicians and patients need to weigh real but limited evidence rather than wait for data that may not arrive soon.

Signs That Your Current Thyroid Drug Is Failing

Thyroid medication "failure" is not always about labs. A patient can have a normal TSH and still feel unwell. The following pattern, across at least three of these criteria, should prompt a treatment review.

Symptom-Based Red Flags

• Persistent fatigue despite TSH in the 1.0 to 2.0 mU/L range for at least 3 months
• Cold intolerance, dry skin, or constipation that has not resolved at goal TSH
• Brain fog or memory complaints rated 4 or higher on a 1-to-10 scale
• Weight gain or inability to lose weight with consistent caloric deficit
• Depression or low mood not explained by another diagnosis

Lab Patterns Worth Reviewing

A free T3 in the lower quarter of the reference range (below 2.4 pg/mL in most lab assays) while TSH is normal may indicate impaired T4-to-T3 conversion [8]. The 2014 ATA guidelines note that "measurement of serum T3 is rarely necessary" for routine monitoring, but the guidelines also acknowledge that "some patients feel better" on combination therapy [1]. Ordering a free T3 alongside TSH and free T4 is reasonable when symptoms persist.

When Symptoms Are NOT the Drug

Before attributing persistent symptoms to levothyroxine failure, clinicians should rule out: iron deficiency (ferritin <30 ng/mL impairs thyroid hormone metabolism [9]), celiac disease (reduces levothyroxine absorption [10]), adrenal insufficiency, and depression. A full workup costs less than months of medication adjustment.

How to Switch From Synthroid to Armour Thyroid Safely

Switching is straightforward if done methodically. There is no universally validated conversion ratio, but the most widely used clinical starting point is 60 mg (1 grain) of Armour Thyroid for every 100 mcg of levothyroxine [11].

Step-by-Step Conversion Protocol

1. Confirm TSH, free T4, and free T3 at baseline before any change.
2. Calculate the initial DTE dose using the 60 mg per 100 mcg ratio, rounding down to the nearest available tablet size (Armour Thyroid is available in 15 mg, 30 mg, 60 mg, 90 mg, and 120 mg tablets).
3. Start the DTE dose as a single morning dose with water on an empty stomach, 30 to 60 minutes before food, coffee, or other medications.
4. Recheck TSH, free T4, and free T3 at 6 to 8 weeks.
5. Titrate in 15 mg increments every 6 to 8 weeks until TSH reaches 1.0 to 2.0 mU/L and symptoms resolve.
6. Consider splitting the daily dose into morning and early afternoon if palpitations occur at peak T3 levels [3].

What to Watch For After Switching

Hyperthyroid symptoms (heart racing, sweating, hand tremor, insomnia) within the first two weeks suggest the starting dose was too high. Reduce by 15 mg and recheck labs at six weeks. A TSH below 0.1 mU/L on repeat testing is a signal to reduce further. Sustained subclinical hyperthyroidism is associated with a 2.8-fold increased risk of atrial fibrillation and reduced bone mineral density, particularly in postmenopausal women [12].

Special Populations That Need Extra Caution

Patients over age 65, those with known coronary artery disease, and anyone with a history of atrial fibrillation should start at a lower DTE dose (30 mg) and titrate more slowly, with TSH rechecked every 4 weeks initially [1]. Adrenal insufficiency must be ruled out or treated before starting DTE because thyroid hormone accelerates cortisol clearance and can precipitate an adrenal crisis [13].

How to Switch From Armour Thyroid Back to Synthroid

Switching in the opposite direction follows the reverse ratio: 100 mcg levothyroxine for every 60 mg of current DTE dose. Because levothyroxine takes 4 to 6 weeks to reach steady state, symptom changes are slow. Recheck TSH at 6 to 8 weeks and adjust in 12.5 to 25 mcg increments [1].

Reasons Patients Return to Levothyroxine

• Consistent supply issues (Armour Thyroid has faced periodic manufacturing shortages)
• Persistent palpitations despite twice-daily dosing
• Preference for a more stable serum T3 profile
• Pregnancy planning (the fixed T4:T3 ratio in DTE makes fine-tuned titration harder during pregnancy, and the 2017 ATA pregnancy guidelines recommend levothyroxine monotherapy [14])

Combination T4 Plus T3 Therapy: The Third Option

Some clinicians offer a middle path: continuing levothyroxine and adding low-dose liothyronine (synthetic T3, brand name Cytomel) separately. This approach allows independent titration of each hormone. A 2019 meta-analysis in Thyroid (8 RCTs, N=1,216) found no significant quality-of-life advantage for combination T4/T3 over T4 alone in an unselected hypothyroid population, but subgroup analyses suggested patients with higher depression scores at baseline showed modest benefit [15].

The ATA does not recommend routine combination T4/T3 therapy but states it may be "considered on a trial basis" in patients who have persistent symptoms on optimized levothyroxine monotherapy after other causes are excluded [1].

Practical Dosing for T4/T3 Combination

A typical starting combination is 75 to 100 mcg levothyroxine plus 5 mcg liothyronine twice daily [15]. The total levothyroxine dose is usually reduced by 25 mcg when liothyronine is added. Recheck TSH, free T4, and free T3 at 6 to 8 weeks. Free T3 should stay within the reference range (2.3 to 4.2 pg/mL in most assays) to avoid supraphysiologic T3 exposure [8].

Dosing and Monitoring Reference Table

| Scenario | Starting Dose | Recheck Labs | Titration Step | |---|---|---|---| | Starting DTE from 100 mcg LT4 | 60 mg DTE | 6 to 8 weeks | 15 mg increments | | Starting DTE from 75 mcg LT4 | 45 mg DTE (round to 30 mg) | 6 to 8 weeks | 15 mg increments | | Returning to LT4 from 60 mg DTE | 100 mcg LT4 | 6 to 8 weeks | 12.5 to 25 mcg increments | | Adding T3 to existing LT4 | 5 mcg liothyronine twice daily | 6 to 8 weeks | 5 mcg increments | | Elderly or cardiac history on DTE | 30 mg DTE | 4 weeks | 15 mg increments |

Drug Interactions and Absorption Issues That Undermine Either Therapy

Before concluding that either drug is failing, absorption must be confirmed. Levothyroxine bioavailability drops by 30 to 40 percent when taken with calcium carbonate, iron supplements, proton pump inhibitors, or cholestyramine [16]. The same interactions affect the T4 component of Armour Thyroid. Patients should take thyroid medication at least 4 hours apart from these agents.

Coffee taken within 30 minutes of levothyroxine reduces absorption by approximately 30 percent in controlled studies [16]. Grapefruit juice and high-fiber meals also reduce absorption, though to a lesser degree.

Malabsorption Conditions

Celiac disease, gastric bypass surgery, and autoimmune gastritis can all reduce levothyroxine absorption significantly [10]. In one study, hypothyroid patients with untreated celiac disease needed a mean of 49% higher levothyroxine doses than controls [10]. Treating the underlying condition often resolves the apparent "levothyroxine failure" without any change in thyroid drug.

Timing and Formulation Fixes

Liquid levothyroxine (Tirosint-SOL) and soft-gel capsule formulations (Tirosint) have higher bioavailability in patients with malabsorption or achlorhydria compared to standard tablets [17]. If absorption is suspected as the problem, switching formulation before switching drug class is a reasonable first step.

What the Guidelines Say and Where Clinician Judgment Fills the Gap

The 2014 ATA guidelines (Jonklaas et al.) remain the primary North American reference document [1]. They state: "Combination T4/T3 therapy should not be used routinely" but also acknowledge that "some patients on T4 therapy continue to have hypothyroid symptoms and feel better when taking desiccated thyroid." This language was a notable shift from earlier editions that did not acknowledge DTE as an acceptable option.

The British Thyroid Association 2019 guidelines similarly acknowledge that "a minority of patients do not feel well on LT4 alone" and permit a "carefully supervised trial" of combination therapy [18].

Neither guideline mandates levothyroxine as the only acceptable treatment. Both require that the switch be clinician-supervised, that TSH remain within range, and that risks be discussed.

The Shared Decision-Making Model

Patient preference is clinically valid. The Hoang 2013 data showing 49% DTE preference versus 19% levothyroxine preference in a controlled setting suggests that preference is not simply a placebo-driven phenomenon [4]. A decision to switch should involve documented discussion of: the limited but positive DTE trial data, the T3 peak and its cardiac implications, the fixed T4:T3 ratio constraint, and the monitoring plan.

Frequently Asked Questions